



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL:  
TELEPHONE:  
FACSIMILE:

1641  
RECEIVED

SEP 03 2002

TECH CENTER 1600/2900  
#4  
9-5-02  
P.2.

(512) 536-3184  
(512) 474-5201  
(512) 536-4598

August 23, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
August 23, 2002	
Date	Steven L. Highlander

COPY OF PAPERS  
ORIGINALLY FILED

Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application No. 10/043,877 entitled "ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES" – Tapas Mukhopadhyay et al.*  
*Our reference: INRP:095US*  
*Client reference: MDA99-067*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C19-C23).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:095US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/cas  
Encl: as noted



COPY OF PAPERS  
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Tapas Mukhopadhyay, Sunil Chada, Abner  
Mhashilkar and Jack A. Roth

Group Art Unit: 1641

Examiner: Unknown

Atty. Dkt. No.: INRP:095US

RECEIVED


SEP 03 2002

TECH CENTER 1600/2900

Serial No.: 10/043, 877

Filed: January 9, 2002

For: ANTIHELMINTHIC DRUGS AS A  
TREATMENT FOR  
HYPERPROLIFERATIVE DISEASES

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
August 23, 2002	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:095US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: August 23, 2002

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:095US

10/043,877

List of Patents and Publications for Applicant's

Applicant

Tapas Mukhopadhyay, Sunil Chada, Abner Mhashikar,  
Jack A. Roth

Filing Date:

Group:

January 9, 2002

1641

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Delatour <i>et al.</i> , "Embryotoxic and antimitotic properties of benzimidazole compounds," <i>Therapie</i> , 31:505-515, 176.
	C20	Lacey <i>et al.</i> , "Activity of benzimidazole against L1210 mouse leukaemia cells: Correlation with in vitro tubulin polymerization assay," <i>Biochem. Pharmacol.</i> , 34:3603-3605, 1985.
	C21	Penman <i>et al.</i> , "Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats," <i>Gut</i> , 34:1559-1565, 1993.
	C22	Ram <i>et al.</i> , "Synthesis and biological activity of certain alkyl 5-(Alkoxy carbonyl)-1H-2-carbamates and related derivatives: A new class of potential antineoplastic and antifilarial agents," <i>Journal of Medicinal Chemistry</i> , 35:539-547, 1992.
	C23	Tobi <i>et al.</i> , "Omeprazole inhibits growth of cancer cell line of colonic origin," <i>Dig. Dis. Sci.</i> , 40: 1526-1530, 1995.

25200216.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)